On June 19, 2019, MiMedx Group, Inc. announced that at its annual shareholders meeting held on June 17, 2019, the shareholders have elected the Company’s nominees: M. Kathleen Behrens Wilsey, K. Todd Newton, Timothy R. Wright, David J. Furstenberg, and Shawn P. George as directors of the Company and the proposals: (1) to amend the amended and restated bylaws of the Company to require the board to hold a meeting on August 19, 2019 for the election of 3 Class III directors and (2) to repeal any amendments to the bylaws adopted by the board subsequent to October 3, 2018 and prior to August 19, 2019 were not approved.
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.